Interim analysis of the phase II study: Noninferiority study of doxorubicin with upfront dexrazoxane plus olaratumab for advanced or metastatic soft-tissue Sarcoma ^A C

Brian A. van Tine, Angela C. Hirbe, Peter Oppelt, Ashley E. Frith, Richa Rathore, Joshua D. Mitchell, Fei Wan, Shellie Berry, Michele Landeau, George A. Heberton, John Gorcsan, Peter R. Huntjens, Yoku Soyama, Justin M. Vader, Jose A. Alvarez-Cardona, Kathleen W. Zhang, Daniel J. Lenihan, Ronald J. Krone

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Sort by
Weight
Alphabetically

Interim analysis of the phase II study: Noninferiority study of doxorubicin with upfront dexrazoxane plus olaratumab for advanced or metastatic soft-tissue Sarcoma ^A C

Fingerprint

Medicine & Life Sciences

Interim analysis of the phase II study: Noninferiority study of doxorubicin with upfront dexrazoxane plus olaratumab for advanced or metastatic soft-tissue Sarcoma A C

Fingerprint

Medicine & Life Sciences

Interim analysis of the phase II study: Noninferiority study of doxorubicin with upfront dexrazoxane plus olaratumab for advanced or metastatic soft-tissue Sarcoma ^A C